Pyxis Oncology has a 1-year low of $0.99 and a 1-year high of $6.18. The firm has a market capitalization of $74.52 million, a price-to-earnings ratio of -1.17 and a beta of 1.11.

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today ...

RBC Capital analyst Leonid Timashev maintained a Buy rating on Pyxis Oncology (PYXS – Research Report) on March 18 and set a price target of $8.00. The company’s shares closed yesterday at $1.07.

Read Our Latest Stock Report on PYXS Pyxis Oncology Trading Up 8.0 % Pyxis Oncology stock opened at $1.21 on Friday. Pyxis Oncology has a 12-month low of $0.99 and a 12-month high of $6.18. The ...